Lercanidipine Bouchara-Recordati

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Bouchara-Recordati, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of hypertension in adult patients across the European market.

GNH USA supplies Lercanidipine Bouchara-Recordati as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium‑channel blocker used in the management of elevated blood pressure.

- Essential hypertension: lowers systolic and diastolic pressure in adults with primary high blood pressure. - Secondary hypertension (adjunct): contributes to blood‑pressure control when hypertension is due to another underlying condition. - Hypertensive patients with cardiovascular risk: helps achieve target pressures as part of a risk‑reduction strategy.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warm sensation, often on the face. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare but reported. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of lips, tongue, or airway. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Blood pressure monitoring: assess baseline and periodic readings. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant antihypertensives: avoid excessive hypotension when combined. - Sudden discontinuation: taper to prevent rebound hypertension. - CYP3A4 inhibitors: review medications that may increase exposure. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma levels. - Concomitant potent vasodilators: risk of additive hypotension. - Grapefruit juice: can increase drug exposure.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Diuretics: may enhance antihypertensive effect. - Beta‑blockers: monitor for combined heart‑rate effects. - NSAIDs: may blunt blood‑pressure reduction. - Digoxin: observe for potential changes in serum concentration.